Schizophrenia remains a major health burden, highlighting the need for new treatment
approaches. We consider the potential for targeting the trace amine (TA) system. We first …

Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target
for neuropsychiatric disorders due to its ability to modulate monoaminergic and …

There are nine subfamilies of TAARs. They are predominantly intracellular, located in the
central nervous system and peripherally. They have a role in homeostasis and rheostasis …

There is a need for innovation with respect to therapeutics in psychiatry. Available evidence
indicates that the trace amine-associated receptor 1 (TAAR1) agonist SEP-363856 is …

Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments
manage the positive symptoms, yet have minimal effects on the negative and cognitive …

Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-
HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough …

Trace amines, a group of amines expressed at the nanomolar level in the mammalian brain,
can modulate monoamine transmission. The discovery of and the functional research on the …

Introduction: The trace amines, endogenous amines closely related to the biogenic amine
neurotransmitters, have been known to exert physiological and neurological effects for …

Trace amines (TAs) such as β-phenylethylamine, p-tyramine, or tryptamine are biogenic
amines found in the brain at low concentrations that have been implicated in various …

Biogenic amines are a collection of endogenous molecules that play pivotal roles as
neurotransmitters and hormones. In addition to the “classical” biogenic amines resulting …